MarketPulse

radiopharmaceutical

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Perspective Therapeutics, Inc.

Perspective Therapeutics Advances Rare Cancer Therapy With 43% Response Rate Data

Perspective Therapeutics reports 43% response rate for neuroendocrine tumor therapy with no serious safety issues, planning 2026 regulatory submissions.
CATXclinical trialcancer treatment
BenzingaBenzinga··Vandana Singh

Telix Pharma Surges on $2.14B Regeneron Deal for Solid Tumor Radiotherapies

Telix Pharma secures $2.14B partnership with Regeneron for solid tumor radiopharmaceuticals while reporting 11% quarterly revenue growth and FDA acceptance of brain cancer imaging application.
TLXREGNFDA approvalsolid tumors
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Radiopharm Theranostics Advances RAD202 Trial to Higher Dose Cohort

Radiopharm Theranostics advances RAD202 radiopharmaceutical trial to higher dose cohort following positive safety review, remaining on track for 2026 Phase 1 completion.
RADXPhase 1 clinical trialoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Perspective Therapeutics to Showcase Cancer Pipeline at Major Spring Biopharma Events

Perspective Therapeutics will present at two major investor conferences in April 2026, highlighting its alpha-emitting radiopharmaceutical pipeline for oncology.
CATXclinical trialscancer treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Monopar Strengthens Balance Sheet With $92M Raise, Eyes 2026 Drug Submission

Monopar reports $13.7M net loss, $140.4M cash reserves funding operations through 2027. Company plans mid-2026 NDA submission for Wilson disease treatment ALXN1840.
MNPRfinancial resultsFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Radiopharm Theranostics

Radiopharm Theranostics Advances Novel Prostate Cancer Therapy With First Patient Dosed

Radiopharm Theranostics doses first patient in Phase 1 trial of RAD 402, a targeted radioimmune therapy for advanced prostate cancer, with data expected H2 2026.
RADXmonoclonal antibodyPhase 1 clinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Perspective Therapeutics to Unveil 2025 Results and Clinical Pipeline Progress

Perspective Therapeutics will release 2025 financial results and clinical pipeline updates on March 16, highlighting progress in its cancer-targeting radiopharmaceutical programs.
CATXfinancial resultsclinical trials